Stem cell proliferation: Ex vivo and in vivo observations

Stem Cells

Volumn 15, Issue SUPPL. 1, 1997, Pages 239-251

  Moore, Malcolm A S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CFU GM; CFU S; Cytokines; Self renewal; Stem cell; Telomerase; Telomeres

Indexed keywords

TELOMERASE;

ANIMAL CELL; CELL POPULATION; CELL PROLIFERATION; CONFERENCE PAPER; ENZYME ACTIVITY; HEMATOPOIESIS; MOUSE; NONHUMAN; PROBABILITY; STEADY STATE; STEM CELL;

ANIMALS; CELL DIVISION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MICE;

ANIMALIA; MURINAE;

EID: 0030685767     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.5530150832     Document Type: Article

References (29)

1. Metcalf D, Moore MAS. Hematopoietic Cells. North Holland Publishing Company, Amsterdam. 1971:1-550.
2. Hendrikx PJ, Martens ACM, Hagenbeek A et al. Homing of fluorescently labeled murine hematopoietic stem cells. Exp Hematol 1996;24:129-140.
3. Necas E, Sefc L, Brecher G et al. Hematopoietic reserve provided by spleen colony-forming units (CFU-S). Exp Hematol 1995;23:1242-1246.
4. Spangrude GJ, Brooks DM, Tumas DB. Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenotype but not function. Blood 1995;85:1006-1016.
5. Moore MAS, Hoskins I. Ex vivo expansion of cord blood derived stem cells and progenitors. Blood Cells 1994;20:468-481.
6. Pawliuk R, Eaves C, Humphries RK. Evidence of both ontogeny and transplant dose-regulated expansion of hematopoietic stem cells in vivo. Blood 1996;88:2852-2858.
7. Muench MO, Moore MAS. Accelerated recovery of peripheral blood cell counts in mice transplanted with in vitro cytokine-expanded hematopoietic progenitors. Exp Hematol 1992;20:611-618.
8. Muench MO, Firpo MT, Moore MAS. Bone marrow transplantation with Interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood 1993;81:3463-3473.
9. Moore MAS. Clinical implications of positive and negative hematopoietic stem cell regulators. Review Stratton Lecture. Blood 1991;78:1-19.
10. + cells from patients with stage IV breast cancer. Blood 1994;84:3567-3574.
11. Schneider JG, Crown JP, Wasserheit C et al. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients. Bone Marrow Transplant 1994;14:877-884.
12. Shapiro F, Yao T-J, Moskowitz C et al. The effects of prior therapy on the in-vitro proliferative potential of stem cell factor plus Filgrastim mobilized CD34-positive progenitor cells. Clinical Cancer Research 1997 (in press).
13. Weaver A, Ryder D, Crowther D et al. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 1996;88:3323-3328.
14. Gordon MY, Blackett NM, Lewis JL et al. Evidence for a mechanism that can provide both short-term and long-term haemopoietic repopulation by a seemingly uniform population of primitive human haemopoietic precursor cells. Leukemia 1995;9:1252-1256.
15. Gordon MY, Lewis JL, Grand FH et al. Phenotype and progeny of primitive adherent human hematopoietic progenitors. Leukemia 1996;10:1347-1353.
16. + cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996;88:3223-3229.
17. Haas R, Witt B, Mohle R et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995;85:3754-3761.
18. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet 1992;339:640-642.
19. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supporting care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;1:277-281.
20. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993;81:2031-2035.
21. + peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 1995;85:566-574.
22. Breems DA, van Hennik PB, Kusadasi N et al. Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells. Blood 1996;87:5370-5378.
23. + hematopoietic progenitors elicited from human fetal liver, umbilical cord blood, bone marrow, and mobilized peripheral blood. J Hematother 1996;5:655-662.
24. Vazir H, Schachter IU, Wei L et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 1993;82:661-667.
25. Vazir H, Dragowska W, Allsopp RC et al. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994;96:9857-9860.
26. Engelhardt M, Albanell J, Kumar R et al. Telomerase upregulation and telomere length in ex vivo expansion cultures of hematopoietic progenitor cells. Blood 1996;88:341a.
27. Shapiro F, Engelhardt M, Ngok D et al. Telomere length shortening and recovery following high-dose chemotherapy with autologous peripheral stem cell rescue. Blood 1996;88:601a.
28. Frey B, Cannizzo S, Crystal RG et al. Expression of human thrombopoietin transgene delivered by an adenovirus based strategy is dependent on host immune competence. Exp Hematol 1996;24:1056.
29. -, require particularly high concentrations of FLT-3 ligand (FL), and are inhibited by excess IL-3. Blood 1996;88:445a.